Xinyuan shares: it is proposed to launch the restricted stock incentive plan in 2022

Synthetic Biology: Who Will Emerge as the Winner?

The 21st century is the century of biology. Synthetic biology is believed to be a ‘World Changing’ industry. But the potential risks like cost control and commercialization pathways are fatefully tied to the ups and downs of countless investment decisions and the destiny of the many new start-ups getting involved. We look forward to seeing an emerging ‘giant’ on the horizon of this exciting industry.

Runjian Signs US$200 Million Overseas AI Inference Contract, Keeping Computing Resources in China

Runjian（润建股份）disclosed on October 18 that its wholly owned subsidiary Wuxiang Yungu（五象云谷）had signed a one-year AI token services contract with an unidentified overseas company. The agreement includes a US$200 million minimum annual purchase commitment, equivalent to approximately CNY 1.338 billion, with computing resources hosted in China and services accessed remotely through an API.

China Proposes Export Restrictions on 23 AI Technologies, Keeps API Services Outside Large-Model Transfer Rules

China’s Ministry of Commerce and Ministry of Science and Technology published proposed additions to the country’s technology-export catalogue on October 16, covering 23 AI technologies. Accompanying guidance distinguishes transfers of restricted technology from services such as overseas API access, while a temporary registration requirement has already taken effect.

Semight Instruments Plans Hong Kong Listing to Broaden Offshore Financing Options

Semight Instruments（联讯仪器）, a Suzhou-based supplier of test instruments and equipment, has secured board approval to pursue an H-share listing on the Hong Kong Stock Exchange’s Main Board. The proposal advances the company’s plans to broaden offshore financing access, although shareholder approval and regulatory procedures remain outstanding.

Bloomage: Injecting Biotechnology into Beauty Care

Listed on the Chinese Star Market in November 2019, Bloomage was trading at CNY 138.01 as of June 24, 2020, over 38% higher than the IPO price of CNY 100.